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SUMMARY 
A major challenge in the current development of complex biotechnological systems 
remains in its miniaturization to enable an efficient and economic use in biomedical 
research. Microphysiological organ-on-a-chip models enter the stage as an enhanced 
in vitro method to emulate physiological processes ex vivo. In addition, this approach 
offers new possibilities to model organ failure and to study systemic inflammatory 
diseases like sepsis. Due to the lack of appropriate treatment options, sepsis is one 
of the leading causes of death in intensive care units. Sepsis-related liver dysfunction 
severely affects the patient survival and causes high mortality underlining the 
importance of this organ in host defense. Therefore, the versatile organ-on-a-chip 
technology could be a promising in vitro tool to investigate the pathophysiological role 
of organs, such as the liver, during inflammation under humanized conditions.  
The objective of this work was the establishment of a human liver-on-a-chip and its 
application as a model of inflammatory hepatic dysfunction. In the first study, four 
major cell types of the liver were integrated in the Multi Organ Tissue Flow (MOTiF) 
biochip and examined by functional as well as morphological characteristics 
(manuscript I). Inspired by the basic microanatomy of the liver sinusoid, human 
umbilical vein endothelial cells and primary human, monocyte-derived macrophages 
were co-cultured with HepaRG and LX-2 cells representing the vascular and hepatic 
cell layer, respectively. A porous membrane served as a culture surface for the 
distinct layers and forms an artificial space of Disse. The combination of vascular 
perfusion and cellular interaction led to functional stabilization and polarization of the 
hepatocytes, which was associated with improved biliary excretion via self-formed 
bile canaliculi, increased albumin and urea synthesis as well as cytochrome P450 
(CYP) 3A4 activity compared to static liver-on-a-chip culture. Moreover, continuous 
evaluation of cellular oxygen consumption measured by luminescence-emitting 
sensor spots enabled the assessment of the metabolic activity.  
To verify the applicability of the liver-on-a-chip model as a new biomedical research 
tool we investigated toll-like receptor (TLR)-mediated inflammation (manuscript II). 
TLR stimulation for three days led to hepatocellular dysfunction accompanied by the 
specific release of the pro-inflammatory cytokine interleukin (IL)-6 as well as the anti-
inflammatory IL-10 depending on the pathogen-associated molecular pattern. 
Incubation with lipopolysaccharide (LPS) further revealed a time-dependent cytokine 
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profile. The results were comparable to data obtained from patients suffering from 
sepsis as well as data from murine sepsis models, where fecal stool samples were 
injected into the peritoneum to trigger systemic inflammation (peritoneal 
contamination and infection, PCI). Hepatocellular dysfunction in our liver-on-a-chip 
model was characterized by a loss of vascular barrier integrity, diminished biliary 
excretion rate and reduced apolipoprotein B expression. Interestingly, hepatic 
damage was prevented by integration of circulating monocytes, which resulted in 
inflammatory resolution. Furthermore, we identified IL-10 as a potential mediator 
directing the polarization state of tissue-resident macrophages to an anti-
inflammatory, regenerative phenotype in the presented model. 
The utilization of organ-on-a-chip applications is limited by their challenging culture 
protocols and time-consuming establishment. Additionally, handling of these in vitro 
models requires expertise, which is necessary to grant reproducibility and reliable 
results. Therefore, we developed novel protocols for hypothermic storage of liver-on-
a-chip models to maintain their microstructure after assembly (manuscript III). Five 
different storage solutions were tested for their ability to preserve morphology and 
function of the respective cell layers. The study confirmed that the preservation of the 
liver model in an adapted formulation of the TiProtec
®
 storage solution is possible for 
up to two days at 4 °C. Apart from the structural conservation, the inflammatory 
responsiveness to LPS was verified by the secretion of tumor necrosis factor, IL-1β, 
IL-10 and IL-6 as well as the characteristic activated macrophage morphology. 
Unfortunately, we were not able to extend the cold storage period beyond two days 
without significantly effecting cell viability and function. Nevertheless, to our best of 
knowledge this was the first successful approach of a liver-on-a-chip preservation.  
Our hepatic model featured characteristics of human tissue samples and clinical 
observations during liver inflammation. Nonetheless, sequential integration of primary 
liver cells will be necessary to assess benefits and drawbacks of this concept. In 
summary, this thesis demonstrates the characterization, application and utilization of 
a human liver-on-a-chip as a new alternative to conventional in vitro and in vivo test 
systems. The complex hepatic microenvironment created in perfused multi-layered 
tissue models was shown to be important for improving cell type specific functions 
closely resembling the in vivo situation. This model has the potential to become a 
valuable alternative to overcome the limitations in translational research and will help 
to close the gap between conventional cell culture and animal experimentation. 
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ZUSAMMENFASSUNG 
Eine der größten Herausforderungen in der aktuellen Entwicklung komplexer bio-
technologischer Systeme ist deren Miniaturisierung zur effizienten und ökonomischen 
Nutzung in der Biomedizin. Mikrophysiologische organ-on-a-chip Modelle sind eine 
verbesserte in vitro Technik zur Untersuchung physiologischer Prozesse ex vivo und 
daher von besonderem Interesse für die Forschung. Außerdem könnte dieses Kon-
zept neue Möglichkeiten zur Abbildung von Organversagen und Untersuchung 
systemischer, inflammatorischer Krankheiten, wie Sepsis, eröffnen. Sepsis ist 
aufgrund der eingeschränkten Behandlungsmöglichkeiten eine der führenden 
Todesursachen auf Intensivstationen. Dabei korreliert die Sepsis-assoziierte 
Leberdysfunktion mit einer schlechten Prognose und hohen Mortalität der Patienten, 
was die Wichtigkeit des Organs in der Immunabwehr unterstreicht. Daher könnte die 
vielseitige organ-on-a-chip Technologie ein vielversprechendes in vitro Werkzeug 
darstellen, um die pathophysiologische Rolle von humanen Organen wie der Leber 
während einer Entzündung zu untersuchen. 
Das Ziel dieser Arbeit war es, ein humanes, biochip-basiertes Leber Modell zu 
etablieren und dessen Tauglichkeit zur Untersuchung inflammatorischer Vorgänge zu 
verifizieren. In der ersten Studie wurden die vier Hauptzelltypen der Leber in den 
Multi Organ Tissue Flow (MOTiF) Biochip integriert und anhand von morpho-
logischen und funktionellen Aspekten charakterisiert (Manuskript I). In Anlehnung an 
die prinzipielle Mikroanatomie eines Lebersinusoids wurden humane Endothelzellen 
der Nabelschnurvene und primäre, aus Monozyten abgeleitete humane Makro-
phagen (vaskuläre Zellschicht) mit HepaRG und LX-2 Zellen (hepatische Zellschicht) 
ko-kultiviert. Dabei diente eine poröse Membran als artifizieller Disse-Raum sowie als 
Kulturoberfläche für die verschiedenen Zellschichten. Die Kombination aus 
vaskulärer Perfusion und zellulärer Interaktion führte zu einer funktionellen 
Stabilisierung und Polarisierung der Hepatozyten. Diese war gekennzeichnet durch 
eine verbesserte biliäre Exkretion durch im Chip selbst ausgebildete Gallenkanälchen 
und Cytochrom P450 (CYP) 3A4 Enzymaktivität sowie einer erhöhten Albumin- und 
Harnstoffsynthese im Vergleich zur statischen Kultur. Zusätzlich konnten durch eine 
kontinuierliche Ermittlung des zellulären Sauerstoffverbrauchs mittels integrierter 
Lumineszenz-emittierender Sensorspots Rückschlüsse auf die metabolische Aktivität 
gezogen werden.  
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Um die Anwendbarkeit des Leber-Modells als neues Werkzeug in der präklinischen 
Forschung darzulegen, wurde über Stimulation von Toll-ähnlichen Rezeptoren (TLR) 
eine Entzündung induziert (Manuskript II). Eine dreitägige Inkubation mit TLR 
Agonisten führte zu einer hepatozellulären Dysfunktion, die in Abhängigkeit vom 
pathogen-assoziierten molekularen Muster zur spezifischen Freisetzung des pro-
inflammatorischen Zytokins Interleukin (IL)-6 sowie des anti-inflammatorischen IL-10 
führte. Weiterführend konnten durch Applikation von Lipopolysacchariden (LPS), 
anhand des zeitabhängigen Zytokinprofils Übereinstimmungen zu Daten von Sepsis-
Patienten und eines murinen Sepsismodells, bei dem durch Injektion von Faeces in 
das Peritoneum eine systemische Inflammation ausgelöst wurde (peritoneale 
Kontamination und Infektion, PCI), nachgewiesen werden. Die hepatische 
Dysfunktion im liver-on-a-chip Modell war mit einem Verlust der Integrität der 
vaskulären Barriere, einer verminderten biliären Exkretionsrate und einer reduzierten 
Apolipoprotein B Expression assoziiert. Interessanterweise konnte durch Integration 
von zirkulierenden Monozyten eine Auflösung des Schadens und damit die 
inflammatorische Regression induziert werden. Zusätzlich wurde IL-10 als ein 
potentieller Vermittler für die Polarisierung der Makrophagen zu einem anti-
inflammatorischen, regenerativen Phänotyp in unserem Modell identifiziert. 
Bis heute ist die Nutzbarkeit von organ-on-a-chip Modellen durch anspruchsvolle 
Assemblierungsprotokolle und die damit verbundene, zeitaufwändige Etablierung 
limitiert. Zusätzlich erfordert deren Handhabung Expertise, um reproduzierbare und 
verlässliche Ergebnisse zu garantieren. Deshalb wurden in dieser Arbeit neue Proto-
kolle zur hypothermalen Lagerung von komplett assemblierten liver-on-a-chip 
Modellen entwickelt, um deren Mikrostruktur zu konservieren (Manuskript III). Im 
Zuge dessen wurden fünf verschiedene Lagerungslösungen hinsichtlich der Auf-
rechterhaltung von Morphologie und Funktion der jeweiligen Zellschichten bewertet. 
Die Untersuchungen zeigten, dass eine Konservierung der Lebermodelle für zwei 
Tage bei 4 °C in einem Derivat der TiProtec
® Lösung möglich war. Außerdem konnte 
anhand der Sekretion des Tumornekrosefaktors, IL-1β, IL-10 und IL-6 einhergehend 
mit der charakteristischen Morphologie der aktivierten Makrophagen ein Erhalt der 
inflammatorischen Responsivität nachgewiesen werden. Leider war es nicht möglich 
die Lagerung ohne Schädigung der Zellschichten auf mehr als zwei Tage zu 
verlängern. Dennoch beschreibt diese Studie nach unserem Wissen zum ersten Mal 
eine Methode zur hypothermalen Konservierung eines liver-on-a-chip Modells.  
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Unser hepatisches Modell wies zu humanen Gewebeschnitten vergleichbare 
Merkmale auf und zeigte Übereinstimmungen zu klinischen Beobachtungen im 
Verlauf einer Leberentzündung. Jedoch ist in Zukunft eine sequenzielle Integration 
von primären Leberzellen nötig, um die Vor- und Nachteile unseres Konzepts zu 
bewerten. Zusammenfassend wurde in dieser Arbeit die Charakterisierung, 
Anwendung und mögliche Nutzung eines humanen biochip-basierten Lebermodells 
als neue Alternative zu konventionellen in vitro und in vivo Testsystemen gezeigt. 
Dabei ist die komplexe Mikroumgebung der mehrschichtigen, perfundierten 
Gewebemodelle entscheidend für eine verbesserte zelluläre Funktion in Annäherung 
an die in vivo Situation. Diese Applikationen stellen eine wertvolle Alternative dar, um 
die limitierte Übertragbarkeit von translationalen Forschungsergebnissen zu 
verbessern und dadurch die Lücke zwischen konventioneller Zellkultur und 
Tierexperimenten zu schließen. 
I N T R O D U C T I O N  | 1 
 
1 INTRODUCTION 
1.1 Microphysiological Models  
To date, translational research and understanding of molecular as well as cellular 
processes of disease progression are highly influenced by the used model system, 
which needs to be considered when interpreting collected data. On the one hand, 
static cell culture can barely mimic the complex physiology of the human body or 
even a single organ. On the other hand, animal models possess a complex systemic 
interaction but the results gained by them show differences in pathophysiological 
mechanisms compared to humans (Seok et al. 2013) or fail to be translated into 
clinical practice (Kingsley and Bhat 2016). Nonetheless, there is an ongoing debate 
about the future of murine models, especially regarding inflammation and sepsis 
(Efron et al. 2015). Most recently, microphysiological systems rapidly emerged in 
biomedical research and have the potential to provide a promising alternative to 
tackle these issues.  
It has been shown that the increased complexity of organ-on-a-chip applications has 
several advantages compared to static in vitro models. This is mainly achieved by a 
combination of microfluidics, tissue engineering and multi-cell culture in biochips 
(Meyvantsson and Beebe 2008). Until now, there are various approaches to mimic 
the physiology of the respective organs. They range from biochip-based cultivation of 
heart, blood-brain barrier, gut, lung or liver tissue up to multi-organ devices in order to 
study systemic interaction (Materne et al. 2015, Coppeta et al. 2016).  
1.1.1 Novel concepts of in vitro liver modeling 
The liver is the central organ regarding the immune response to pathogens and 
biotransformation of drugs. Hence, a set of various cell types is necessary to fulfill 
these diverse functions. With approximately 80 %, the hepatocytes contribute the 
largest amount of cells to the liver tissue volume (Ishibashi et al. 2009). In addition, 
non-parenchymal cells (NPCs), namely liver sinusoidal endothelial cells (LSECs), 
hepatic stellate cells (HSCs) and Kupffer cells (KCs), are essential to maintain liver 
physiology and immunological homeostasis. Therefore, it is supposed that multi-
cellular liver-on-a-chip models are a valuable new strategy to mimic functional 
aspects of the hepatic microenvironment in vitro, possibly improving the outcome of 
disease and toxicity studies (Vernetti et al. 2016, Starokozhko and Groothuis 2017).   
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1.1.1.1 Regulation of hepatic function by NPCs 
Physiologically, hepatocytes and NPCs closely interact to fulfill a variety of functions 
as a mutually dependent unit (Ishibashi et al. 2009). One of the most prominent 
features of the liver is its drug metabolizing capacity. In general, the process of 
biotransformation can be divided into three phases: phase I (modification), phase II 
(conjugation) and phase III (transport and excretion). Before all molecules get in 
contact with hepatocytes they must pass the liver sinusoids, which are lined with 
LSECs. These cells form a selective barrier to prevent the hepatic parenchyma from 
vascular shear stress. Moreover, they are involved in the recruitment of circulating 
immune cells during liver injury, enable the exchange of nutrients as well as drugs 
with hepatocytes via fenestrations and scavenge different molecules from the blood 
(Poisson et al. 2017).  
Monoculture of primary hepatocytes rapidly results in dedifferentiation accompanied 
by a loss of important phase I and II enzyme activities (Rodríguez-Antona et al. 2002, 
Chen et al. 2012, Godoy et al. 2013). In contrast, co-culture with LSECs led to long-
term stabilization of native cytochrome P450 (CYP) 1A1 activity (Bale et al. 2015a). 
The authors concluded that introduction of extracellular matrix (ECM) and cellular 
interaction were critical for the maintenance of hepatocyte function in their model. 
Furthermore, it was observed that LSECs could prevent unfavorable HSC activation 
through paracrine signaling via vascular endothelial growth factor (Deleve et al. 
2008). Nonetheless, activation of quiescent HSCs in pathophysiological states results 
in an increased production of extracellular matrix aligned with a secretion of several 
cytokines, important for regulating hepatic damage and tissue repair (Weiskirchen 
and Tacke 2014). Krause et al. (2009) showed that hepatocyte differentiation in vitro 
was stabilized in co-culture with HSCs. Additionally, it was investigated that a cross 
talk between these cell types is bidirectional, notably under inflammatory conditions 
(Coulouarn et al. 2012). Due to these observations the interaction of different NPCs 
with hepatocytes appears to be necessary to support hepatic function and to regulate 
their pathophysiological response. This statement is fostered by the presence of KCs 
as specialized macrophages, which were able to enhance albumin and urea 
synthesis in co-culture with hepatocytes (Zinchenko et al. 2006) and represent 
important immunological regulators in the liver (Sica et al. 2014). 
1.1.1.2 Liver-on-a-chip as a new research tool  
Mimicking the liver in vitro is still a challenge and far from being fully developed and 
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validated. Despite the cellular composition and related arrangement, micro-
physiological systems comprise several technical variables, e.g. the design and 
material of the biochip device. Further, exogenous factors like shear stress, 
oxygenation and nutrient supply need to be monitored continuously to emulate a 
stable hepatic microenvironment. Hence, it is necessary to analyze the specific 
physiological characteristics of the human sinusoid to cover a wide range of different 
aspects by liver-on-a-chip modeling (Figure 1). Dependent on the application, 
different cell sources (i.e. primary cells, cell lines) and proper evaluation of their 
individual advantages as well as disadvantages is necessary.  
 
Figure 1. Important characteristics of the liver that need to be considered in the 
establishment of a microphysiological hepatic in vitro model. Figure modified from Iredale et 
al. (2007). 
 
To protect the hepatic parenchyma from harmful shear stress different cell culture 
strategies were applied. McCarty et al. (2014) used ultrathin layers of modified 
collagen to cover primary hepatocytes. Their results demonstrated that hepatocyte 
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morphology and function were maintained for up to 14 days under slow perfusion 
rates of 20 µl/h (McCarty et al. 2014). An extension of this approach consisted in the 
integration of LSECs as a barrier with a physiological ECM mimicking the space of 
Disse, similar to the in vivo situation. Kang et al. (2015) emulated the sinusoidal 
structure by use of single channel cell culture chambers with stacked endothelial cells 
(ECs) and hepatocytes divided by a layer of BD MatrigelTM. Additionally, the authors 
of this study compared their model with a dual channel setup where the vascular and 
hepatic cells grew on different sides of a porous membrane. The membrane served 
as a permeable cell culture surface, providing an artificial space of Disse for a better 
control of cellular growth, cell-medium interaction and long term stabilization of the 
microenvironment (Kang et al. 2015). Prodanov and colleagues further adapted this 
approach by integration of U937 (tissue-resident macrophages) and LX-2 (stellate 
cell line), additionally to ECs and primary hepatocytes in two distinct layers. They 
were able to maintain this liver-on-a-chip model for 28 days with stable albumin and 
urea secretion as well as CYP3A4 activity (Prodanov et al. 2016). In a similar device 
with primary murine cells it was also proven that the presence of all four major 
hepatic cell types led to a higher amount of recruited neutrophils after 
lipopolysaccharide (LPS) stimulation (Du et al. 2017), most likely via up-regulation of 
adhesion molecules in LSECs (Edwards et al. 2005). This promising membrane-
based approach with a vascularized compartment and a separated epithelial cell 
layer was also used for other organ models, i.e. emulation of the intestine (Kim et al. 
2016), lung (Jain et al. 2018) and the blood-brain barrier (Raasch et al. 2016).  
Besides cellular adaptations within microphysiological systems, exogenous factors 
play an important role in modulating the microenvironment. First of all the biochip 
material, used for fabrication, needs to be considered. Various microfluidic cell 
culture devices were made of polydimethylsiloxane (PDMS) due to practical 
advantages in processing of the material (Leclerc et al. 2003, Maschmeyer et al. 
2015, Du et al. 2017, Kang et al. 2017). However, the unspecific binding capacity of 
PDMS for hydrophobic drugs as well as other molecules could cause variable drug 
concentrations exposed to cells and tissues possibly affecting the obtained results 
from associated drug testing (Toepke and Beebe 2006). Therefore, Marx and 
colleagues suggested the use of materials already established for standard cell 
culture dishes, such as polystyrene (PS), as the future of organ-on-a-chip 
manufacturing (Marx et al. 2016). Another important step to promote 
microphysiological systems is the integration of miniaturized sensors allowing a 
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continuous monitoring of the critical cell culture parameters thereby contributing to 
the formation of an organ-specific microenvironment and related cell function (Zhang 
et al. 2017). Overall, the utilization of biochip-based organ models is critically affected 
by two variables, the choice of cellular composition and consideration of exogenous 
influencing factors. 
  
1.2 Liver inflammation – aspects in biomedical 
research 
1.2.1 Pathophysiological role of the liver in sepsis 
Recently, Singer and colleagues defined sepsis as a cause of infection that leads to 
life-threatening organ failure accompanied by a dysregulated immune response 
(Singer et al. 2016). Recent clinical data indicate that severe courses of systemic 
inflammation and multi-organ failure still lead to mortality rates over 40 % 
(Fleischmann et al. 2016). Additionally, there is evidence that liver dysfunction during 
sepsis is associated with a poor prognosis of patients (Brun-Buisson et al. 2004, 
Abraham et al. 2005).  
Sepsis-associated liver dysfunction leads to metabolic and functional adaptation of 
the liver cells as a consequence of various factors modulating the immune response. 
Bacterial clearance and hepatic immune surveillance are mainly regulated at the 
endothelium of the liver sinusoid (Brunt et al. 2014). The complex interaction of 
immunological, physiological and molecular mechanisms however is still not fully 
understood and needs to be further elucidated. 
1.2.2 Hepatocellular dysregulation during inflammation 
Liver dysfunction is driven by an exuberant immune reaction associated with a loss of 
synthesis and clearance capacity of hepatocytes due to cholestasis, cholangitis, 
fibrosis or ischemia (Strnad et al. 2017). Basic clinical indicators for liver damage with 
functional impairment are increased serum concentrations of hepatic transaminases 
(Bakker et al. 2004) and bilirubin (Singer et al. 2016). Further, hepatic dysfunction is 
closely related to signaling of hepatocytes and NPCs, because LSECs as well as the 
tissue-resident KCs are in the first line of defense encountering pathogens. 
Additionally, increased expression of vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1) and E-selectin leads to active recruitment 
of circulating immune cells during inflammation (Wu et al. 2001).  
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LSECs clear macromolecular waste and scavenge circulating antigens from the 
blood (Smedsrød 2004, Schurich et al. 2009), whereas KCs engulf cellular debris and 
microorganisms like S. aureus or E. coli. (Falasca et al. 1996, Ono et al. 2006). 
These functions are realized partly via pathogen recognition receptors located on the 
surface of NPCs as well as parenchymal cells (Szabo et al. 2006). As an example, 
toll-like receptors (TLRs) are involved in the recognition of pathogen-associated 
molecular patterns (PAMPs) and the initiation of signaling cascades that trigger 
specific inflammatory reactions depending on the individual receptor involved (Ospelt 
and Gay 2010). LPS is a well characterized activator of TLR-4 and requires 
complexation with the LPS-binding protein, the receptor cluster of differentiation (CD) 
14 and MD-2 (Lu et al. 2008). Stimulation of TLR-4 activates the transcription factors 
NFκB and interferon (IFN) regulatory factor 3 leading to the release of different IFNs 
and other pro-inflammatory cytokines (Takeuchi and Akira 2010). The release of 
interleukin (IL)-1β, tumor necrosis factor (TNF), IFN-γ or IL-6 by immune cells (i.e. 
macrophages, monocytes, natural killer cells) in turn triggers the production of 
various acute phase proteins in hepatocytes (Tacke et al. 2009). The mentioned 
chemokines possess pleiotropic functions and are centrally involved in the regulation 
of immunological processes within the liver (Shah et al. 2006).  
In the course of inflammation, the metabolic activity of hepatocytes is severely 
deregulated. In vitro, LPS stimulation of hepatocytes altered albumin synthesis 
(Wang et al. 2004) and decreased mRNA levels as well as related activity of several 
CYP-enzymes (Aitken and Morgan 2007, Rubin et al. 2015). Moreover, bile 
canaliculi-associated transporter multi drug resistance protein-2 (MRP-2) protein 
expression in human liver slices is reduced after 24 h of LPS treatment (Elferink et al. 
2004). These observations support the assumption that liver inflammation involves a 
complex cascade of immunomodulatory signaling molecules driven by NPCs 
ultimately affecting the function of hepatocytes. 
1.2.2.1 Macrophage polarization and regulation 
KCs account for 80-90 % of all tissue macrophages of the human body (Ishibashi et 
al. 2009), which highlights their importance in balancing the immunological 
homeostasis of the liver. This is supported by the fact that macrophage depletion in 
mice led to reduced hepatic fibrogenesis after LPS challenge (Seki et al. 2007) and 
insufficient resolution of fibrosis during healing (Duffield et al. 2005). KCs form a 
heterogeneous population depending on their origin and physiological state of the 
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hepatic microenvironment (Tacke and Zimmermann 2014). Furthermore, polarization 
of tissue-resident macrophages in the liver guides their function and molecular 
signaling (Figure 2). The classical activated M1-phenotype is involved in inflammation 
by secretion of pro-inflammatory cytokines, such as TNF and IL-1β, as well as 
inducible nitric oxide synthase (Sica et al. 2014). In contrast, M2 macrophages 
mediate the resolution of liver inflammation, i.e. through efficient phagocytosis of cell 
debris and the secretion of transforming growth factor-β as well as IL-10 (Wynn and 
Barron 2010, Krenkel and Tacke 2017). 
 
Figure 2. Schematic overview of macrophage functions depending on their polarization state 
in the liver (M1/M2). Figure modified from Sica et al. (2014). 
 
Macrophage polarization states are well regulated and far from being strictly 
distinguishable. Intermediary conditions were defined by Mantovani and colleagues 
who classified M2 macrophages into different subtypes dependent on the inducer 
and related functional response (Mantovani et al. 2004). The difficulty of macrophage 
distinction was further highlighted by Barros et al. (2013) who examined the 
expression of CD68 and CD163 in respect to M1 and M2 polarization. They 
concluded that different activation states co-exist in their disease model, which 
supports the assumption of at least partially overlapping activation patterns (Barros et 
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al. 2013). Another critical regulator of inflammatory signaling is the possible transition 
of tissue-resident macrophages during inflammation. In this regard, IL-10 is 
considered to be an important regulator of macrophage metabolism accompanied 
with inhibition of their inflammatory response (Ip et al. 2017). In contrast, recent 
results indicate that a direct polarization change might not be possible, as INFγ-
induced M1 macrophages failed to shift to the M2 phenotype after IL-4 treatment (van 
den Bossche et al. 2016). In the same study they rather suggested a replacement of 
macrophages by circulating monocytes instead of tissue macrophage repolarization. 
1.2.3 Models of sepsis and sepsis-related liver 
dysfunction 
Due to the complexity of hepatic inflammation, understanding of cellular and 
molecular regulators is still a challenge in translational medicine. Human in vitro 
models of the liver largely differ in their ability to mimic the hepatic microphysiology. 
Thus, Dejager and colleagues propagated the murine cecal puncture and ligation 
model as the gold standard for sepsis research, due to the similarities in regard to the 
human pathophysiology (Dejager et al. 2011). Mimicking systemic inflammation in an 
animal organism however possesses important drawbacks, such as interindividual 
gene changes in response to i.e. burn, trauma or endotoxemia, which are 
differentially regulated compared to men (Seok et al. 2013). Furthermore, there is 
evidence that mice have a higher resistance to PAMPs, i.e. LPS, than humans (Fink 
2014). To overcome species-related differences, transgenic mice should serve as a 
host for the engraftment of myeloid cells (Rathinam et al. 2011, Willinger et al. 2011) 
or HSCs (Brehm et al. 2012) to “humanize” the observed immunological response. 
But this genetic modification leads to certain disorders accompanied by inadequate 
cytokine signaling (Rongvaux et al. 2013).  
Humanization of mice is quite ambitious and ethically questionable. Therefore, 
human liver-on-a-chip models are a promising alternative for emulation of host 
defense and biotransformation during hepatic inflammation. These microphysiological 
systems generate complex 3D tissue structures with related functional improvements, 
critical for the response to PAMPs. This was proven by the sinusoidal in vitro model 
of Bale et al. (2016) who observed an adapted release of IL-10 and TNF after LPS 
stimulation depending on the presence of hepatocytes and NPCs. Their results 
showed the advantage over in vivo models, where individual contribution of cell types 
to the inflammatory response can hardly be distinguished (Bale et al. 2016). 
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Microfluidically supported cell culture further creates opportunities to integrate 
specific, circulating leucocyte subtypes as immunomodulatory elements. In this 
regard ICAM-1 and CXCL10 were identified as important mediators of T-cell 
recruitment to LSEC monolayers during viral infection (Bruns et al. 2015). Du et al. 
(2017) proved that neutrophil attraction to the hepatic endothelium is increased in a 
multi-cellular liver-on-a-chip compared to LSECs alone. Further, they suggested a 
direct correlation of complexity and microphysiology, which could be critical to 
investigate the course of inflammation in vitro (Du et al. 2017). In contrast, liver-on-a-
chip applications are still limited by the use of murine cells (Kang et al. 2015, 
Prodanov et al. 2016), lack of important cell types (Toh et al. 2009, Kang et al. 2017) 
or non-physiological cellular arrangement (Vernetti et al. 2016). Thus, their utilization 
for studying hepatic inflammation close to the human physiology is still lacking and 
creates the need for new in vitro approaches to remedy existing drawbacks. 
 
1.3 Hypothermal liver-on-a-chip preservation  
Microphysiological liver-on-a-chip models constantly emerge in biomedical research. 
Assembly and microenvironmental control of those in vitro systems is still challenging 
and requires particular expertise as well as experience. To date, there is no available 
technique to preserve the structure and metabolic function of such models for 
distribution between different facilities. A possible solution for this problem could be 
the storage under hypothermal conditions, which is widely used to create a 
morphological and metabolic stasis of liver cells, tissues and different organs for 
medical or research purposes (Kozlova et al. 2003, Guibert et al. 2011, Pless et al. 
2012). Especially in transplantation medicine hypothermal preservation is a 
requirement to prevent a rapid loss of viability and tissue damage (Guibert et al. 
2011).  
In the past, various storage solutions were used to maintain the liver function 
efficiently. Two of the most prominent solutions are the University of Wisconsin 
solution (UW) and histidine-tryptophan-ketoglutarate solution (HTK/Custodiol), which 
showed comparable post-transplant outcomes after cold storage (O'Callaghan et al. 
2014). Both include specific ingredients to tackle cold-induced tissue alterations. HTK 
is characterized by its strong buffering capacity through histidine, low ion 
concentrations (Na+, K+ and Mg2+) and minimal viscosity allowing rapid cooling as 
well as organ flushing. In contrast, UW has a higher viscosity and is supplemented 
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with adenosine as a precursor for adenosine triphosphate (ATP), antioxidants and 
osmotic regulators (lactobionate) to prevent cell swelling (Guibert et al. 2011). In this 
regard, these solutions have proven to be applicable for whole liver transplantation 
and were able to prevent cellular damage. In contrast to the medical use of organ 
preservation, which needs to be approved for surgery, cold storage of hepatic cells 
and small tissue samples for preclinical research can be individualized dependent on 
the utilization.  
Human hepatocytes were stored efficiently in the HTK derivative Custodiol-N over 
two weeks. This chloride-rich solution, supplemented with the iron chelator 
deferoxamine, had advantages in metabolic recovery of the cells compared to the 
UW (Pless et al. 2012). Further, Custodiol-N was able to increase viability of ECs 
after cold storage compared to HTK (Wille et al. 2008). In contrast to UW and HTK, it 
is characterized by a lower buffer capacity and a higher amount of ions, which 
supports the idea of individualization dependent on the size and complexity of the 
preserved material. Novel approaches in liver tissue engineering enabled the 
implementation of parenchymal cells and NPCs that require advanced storage 
protocols. Hypothermal preservation represents a promising storage strategy for pre-
assembled microphysiological systems and potentially offers a better accessibility to 
organ-on-chip technology by a larger field of researchers. 
1.3.1 Cellular alterations during cold storage 
Ultimately, hypothermal preservation results into a loss of cell viability over time. This 
could be explained by the fact that cold storage does not fully stop the cellular 
metabolism. Thus, the reduced metabolic activity of cells still leads to continuous 
accumulation of several meta- and catabolites even under cold conditions. In the 
1990’s it was believed that cell death during hypothermal preservation is a result of 
the ATP shortage that causes Na+/K+-ATPase blocking and finally cellular edema 
(swelling) through excessive Cl- influx (Blankensteijn and Terpstra 1991). However, 
this mechanism was controversial, because of the cell-type specific variations 
dependent on the chloride concentration (Rauen et al. 2007a, Wille et al. 2008). 
Other studies showed that iron-dependent formation of reactive oxygen species 
(ROS) represents a main mediator of cold-induced apoptosis and cell damage, 
involving i.e. chromatin condensation, DNA fragmentation and a loss of plasma 
membrane integrity of ECs and hepatocytes (Rauen et al. 1999, Rauen et al. 2000). 
Thereby, cellular alterations are related to the redox-active, chelatable, intracellular 
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iron pool, which is increased shortly after hypothermal storage (Rauen et al. 2000), 
causing mitochondrial permeability transition (Rauen et al. 2004). Furthermore, cold-
induced cell death triggers the release of damage-associated molecular patterns 
(DAMPs) leading to the unfavorable activation of different immune cells, commonly 
observed during ischemia and reperfusion of liver grafts (Le Moine et al. 2000, 
Tomiyama et al. 2008, Kimura et al. 2016). This causes damage to hepatocytes and 
ECs through various humoral factors (Abu-Amara et al. 2010). In summary, three 
important mediators affect cellular injury during cold storage: iron-dependent 
apoptosis, impaired intracellular ion homeostasis and cell death-related activation of 
immune cells (Figure 3). 
 
Figure 3. Important factors of cellular damage during cold storage: A) Mitochondrial damage 
through ROS formation due to increased intracellular redox-active iron; B) Disturbed ion 
transport affecting intracellular homeostasis; C) DAMP release and immune cell activation. 
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1.3.2 Protective effect of storage solution components on 
liver cells 
In order to prevent cold-induced alterations, specific supplementation of storage 
solutions is necessary for an optimized protection. As mentioned earlier, iron-
dependent cell damage is a main trigger of cold-induced apoptosis (Rauen et al. 
2000). It was observed that membrane permeable iron chelators, such as 
deferoxamine and LK614, markedly increased viability of ECs after storage at 4 °C 
and contributed to an improved mitochondrial membrane potential (Wille et al. 2008, 
Zatschler et al. 2009). Their protective effect was also proven for primary human 
hepatocytes, which displayed significantly reduced lactate dehydrogenase (LDH) 
release after seven days of hypothermal storage (Pless et al. 2012). Furthermore, 
injury of whole rat livers was diminished by deferoxamine, demonstrating the 
applicability of these components for complex tissue preservation (Arthur et al. 2013). 
In contrast to the clear benefit of iron chelators on cell viability, adaptation of the ion 
concentrations needs to be evaluated carefully. High chloride concentrations were 
shown to be advantageous for cold-preservation of ECs (Wille et al. 2008) and 
human hepatocytes (Pless et al. 2012). Surprisingly, LDH release was decreased in 
murine hepatocytes stored in solutions with reduced chloride (Rauen et al. 2007b). 
This species-related effect is not fully understood and might be the result from a 
complex alteration of different ion-dependent transporters during hypothermal 
storage. However, there is evidence that a stable intracellular ion homeostasis is 
beneficial for hypothermal storage of cells and tissues (Kozlova et al. 2003).  
Despite the mentioned additives and adjustments, novel strategies emerge for further 
improvement of cold storage. Recently, polyethylene glycol (PEG; 35 kDA) 
supplementation of UW was found protective against lipid peroxidation in 
hepatocytes, making it a promising additional component (Puts et al. 2015). 
Furthermore, adjustment of pH to a mild acidosis (Nishimura et al. 1998) and 
substitution of toxic buffer components such as histidine (Rauen et al. 2007b) 
improved the applicability of hypothermal storage solutions. To support the 
preservation of the vascular endothelium, the composition of Custodiol-N was 
optimized (commercially available as TiProtec®). This solution was successfully 
utilized for storage of human blood vessels (Garbe et al. 2011) as well as murine 
hepatocytes (Pless-Petig et al. 2012).
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2 AIM OF THESIS 
The main objective of this thesis was the establishment of a microphysiological liver-
on-a-chip to study inflammation-related dysfunction as a new tool and alternative to 
conventional cell culture methods. Most hepatic in vitro models lack the physiological 
complexity thereby affecting their outcome, usefulness and benefit in biomedical 
research (LeCluyse et al. 2012). Therefore, the versatile organ-on-a-chip technology 
is a promising tool to mimic the microenvironment of the human liver with complex 
cellular interaction, thereby creating benefits for the investigation of 
pathophysiological conditions (Ingber 2016). Furthermore, monocytes will be 
perfused and investigated due to the critical involvement of leucocytes in 
immunological signaling during hepatic inflammation (Oo et al. 2010). Liver-on-a-chip 
assembly is associated with complex and challenging culture protocols, which are 
important for a beneficial utilization of this technology. Cold storage is already used to 
preserve the function of liver cells and tissues (Hart et al. 2005, Ostrowska et al. 
2009). Thus, this method might be suitable to maintain microphysiological models 
and enhance their applicability. 
 
Specific objectives of the thesis were: 
- Establishment of a human liver model including ECs, tissue-resident 
macrophages, stellate cells and hepatocytes in a microfluidically perfused 
biochip (manuscript I) 
- Morphological and functional characterization of the biochip-embedded liver 
tissue (manuscript I) 
- Integration of oxygen sensors for monitoring of metabolic activity of liver-on-a-
chip models (manuscript I) 
- Establishment of a disease model of inflammation-associated hepatocellular 
dysfunction (manuscript II) 
- Integration of circulating monocytes (manuscript II) 
- Development of novel hypothermal storage solutions and protocols for liver-
on-a-chip models (manuscript III) 
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3.1 Manuscript I 
 
A microfluidically perfused three dimensional human liver 
model 
 
Rennert K, Steinborn S, Gröger M, Ungerböck B, Jank AM, Ehgartner J, Nietzsche S, 
Dinger J, Kiehntopf M, Funke H, Peters FT, Lupp A, Gärtner C, Mayr T, Bauer M, 
Huber O, Mosig AS 
 
Published in: 
Biomaterials, 2015, 71:119-131. 
 
Here we described the establishment of a biochip-based sinusoid model of the 
human liver. Based on a porous membrane, mimicking the space of Disse, we 
implemented vascular endothelial cells (HUVECs) and primary human, monocyte-
derived macrophages in co-culture with a separate layer containing stellate cells (LX-
2) and hepatocytes (HepaRG). Vascular perfusion and integration of non-
parenchymal cells improved hepatocyte polarization comparable to primary human 
tissue. Morphological features of the artificial liver tissue were analyzed by 
immunostaining of the central hepatic markers CYP3A4, MRP-2 and transferrin. 
Within the multilayered, three-dimensional liver model, hepatocytes displayed 
improved MRP-2 transporter activity, a higher density of microvilli at the cell surface 
and enhanced drug metabolization compared to static liver-on-a-chip culture. 
Furthermore, measurement of oxygen saturation in the media by luminescence-
emitting sensor spots was used to evaluate the metabolic activity of cells in our 
model. In conclusion, the microphysiological model of the human liver holds the 
potential as a novel and valuable tool for in vitro studies under physiological 
conditions. 
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Manuscript I – Supplementary information 
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3.2 Manuscript II 
 
Monocyte-induced recovery of inflammation-associated 
hepatocellular dysfunction in a biochip-based human liver 
model 
 
Gröger M, Rennert K, Giszas B, Weiß E, Dinger J, Funke H, Kiehntopf M, Peters FT, 
Lupp A, Bauer M, Claus RA, Huber O, Mosig AS 
 
Published in: 
Scientific Reports, 2016, 6:21868. 
 
In this study the liver-on-a-chip model was used to evaluate TLR-mediated 
hepatocellular dysfunction. Stimulation with TLR-1/2, 4 and 9 agonists led to specific 
release of pro- and anti-inflammatory cytokines. The resulting loss of vascular 
endothelial cadherin (VEC) indicates an impairment of the endothelial barrier. 
Furthermore, hepatic damage was confirmed by the diminished expression of the 
biliary transporter MRP-2 and apolipoprotein B (ApoB) of the hepatocytes. It was 
shown that perfusion of primary monocytes restored liver-on-a-chip function, 
associated with a recovery of albumin as well as urea synthesis, diminished cell 
death and restored biliary excretion via self-formed bile canaliculi in the HepaRG cell 
layer. The observed pathophysiological conditions were comparable with data 
obtained in the murine sepsis model of peritoneal contamination and infection (PCI) 
as well as in clinical observations of septic patients. Thus, the model proved its ability 
to mimic inflammation-related hepatic dysfunction as well as immune cell-dependent 
liver regeneration. It thereby offers novel options for the elucidation of the underlying 
signaling processes and creates new opportunities in the development of tailored 
treatment strategies for sepsis-associated liver failure.  
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3.3 Manuscript III 
 
Preservation of cell structure, metabolism and 
biotransformation activity of liver-on-chip organ models by 
hypothermic storage  
 
Gröger M, Dinger J, Kiehntopf M, Peter FT, Rauen U, Mosig AS 
 
Published in: 
Advanced Healthcare Materials, 2018, 7(2).  
 
Cryopreservation is a valuable tool to maintain the viability and function of explanted 
organs, i.e. for liver transplantation. For the first time we here describe a method for 
hypothermal storage (4 °C) of a microphysiological human liver model for up to two 
days. Evaluation of five different formulated solutions revealed best results for an 
adapted derivative of the TiProtec
®
 solution complemented with PEG, iron chelators 
and a balanced composition of physiological ions (including Ca2+, Cl-, Mg2+ and K+). 
This solution was shown to preserve the morphology, metabolism and immune 
response of liver-on-a-chip models after cold storage. No alterations of cell function 
were found for barrier integrity (VEC staining), hepatocyte-specific bile canaliculi 
function (5 (and 6)-carboxy-2′,7′-dichlorofluorescein (CDF) secretion rate) and 
CYP3A4 activity (midazolam turnover) after storage, compared to fresh models. 
Furthermore, immune cell activity in response to LPS stimulation was fully maintained 
as proven by the release of pro-inflammatory cytokines and its effect on metabolic 
alterations in hepatocytes. Taken together, this new approach showed feasibility of 
hypothermal storage for the preservation complex biochip-based liver tissues. The 
novel storage protocol will allow a broader use of these microphysiological models, 
i.e. in routine drug testing, and contribute to foster its application as a real alternative 
to animal experimentation. 
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4 DISCUSSION 
For this thesis, a microphysiological human liver-on-a-chip was established to study 
mechanisms of liver inflammation under in vivo-like conditions. Still, emulation of the 
human physiology is a major challenge in pre-clinical research, which intensifies the 
need for new in vitro tools to overcome the limitations of available applications, i.e. 
animal experimentation. This tendency is reinforced by the ongoing and controversial 
debate about the use of in vivo models limiting their applicability for purposes of 
translational medicine (Seok et al. 2013, Takao and Miyakawa 2015, Warren et al. 
2015). Murine models display a complex physiology with desirable organ-interactions 
creating a beneficial tool to study diseases and their impact on the entire organism. 
However, their interspecies differences e.g. in the immune system reduce the 
transferability of the obtained results to humans (Mestas and Hughes 2004). To 
overcome these issues microphysiological models are a promising approach to 
increase the relevance of in vitro experimentation by reverse engineering of human 
organs (Ingber 2016). This organ-on-a-chip concept possesses the potential to 
emulate complex physiological processes, thereby getting closer to mimic the 
function of human organs ex vivo.  
  
4.1 Liver-on-a-chip - complexity matters 
The concept of our microphysiological in vitro liver model is inspired by the structure 
of the human liver sinusoid. In this thesis, it was realized by the use of a perfused 
vascular cell layer, containing HUVECs and macrophages, physiologically protecting 
the HepaRG and LX-2 cells from shear stress. A porous membrane, already used for 
co-culture of ECs with hepatocytes (Kang et al. 2013, Bale et al. 2016), served as cell 
substrate providing the space of Disse between the endothelial lining and the 
parenchyma (Kang et al. 2017). This cellular arrangement and the vascular perfusion 
enabled intercellular communication, stable oxygenation, optimal supply with 
nutrients and efficient removal of cellular waste products.  
4.1.1 Biochip design and technical variables 
The passive support of the static hepatic chamber in our model creates a low media 
to cell ratio, which is considered to be an important parameter of microphysiological 
systems (Wikswo 2014). A non-physiological high media to cell ratio increases the 
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dilution of secreted paracrine signaling molecules (Faley et al. 2008) and metabolites 
of biotransformation (Bale et al. 2015b). With a rate of approximately 0,4 nl/cell in the 
bottom co-culture chamber of HepaRG and LX-2 cells the characterized liver-on-a-
chip is suitable for efficient intercellular signaling as well as investigation of 
accumulating CYP-associated metabolites like 1-OH-midazolam and 4-hydroxy-
diclofenac. Furthermore, the limited amount of cell culture media restricts the 
availability of nutrients like glucose, which is supposed to induce insulin resistance 
and to affect CYP-activity of primary human hepatocytes (Davidson et al. 2016). 
Additionally, our system allows variable adjustment of the perfused media and the 
associated oxygen saturation in the bottom chamber. 
As already mentioned translucent PDMS is commonly used for manufacturing biochip 
devices but it exhibits unspecific binding properties (Toepke and Beebe 2006, van 
Meer et al. 2017). Van Midwoud and colleagues determined a reduced recovery of 
testosterone and 7-hydroxycoumarin in PDMS devices, whereas the viability of 
HepG2 liver cells was almost similar compared to PS and cyclic olefin copolymer 
(COC) (van Midwoud et al. 2012). To avoid potential alterations regarding an 
unspecific binding of liver metabolites, the chosen material of the Multi Organ Tissue 
Flow (MOTiF) biochip was, dependent on its application, PS or COC. Integration of 
luminescence-emitting sensor spots allowed continuous online-measurement of 
oxygen saturation in the media within the respective chambers of each biochip. It was 
observed that microfluidic devices made of PS have higher oxygen permeance than 
COC-based platforms (Byrne et al. 2014). Similar results were obtained by oxygen 
measurements under static conditions in our liver biochips. The PS-based devices 
showed a constant diffusion of oxygen into the media, whereas the oxygen saturation 
of the COC biochip decreased below 5 % after 1 h in the statically cultured hepatic 
chamber. Additionally, these hypoxic conditions were associated with ATP depletion 
in our model, a known characteristic of ischemic injury (Dagher 2000). This was 
confirmed by calculation of a high ADP/ATP ratio, indicating hepatic cell apoptosis. 
After application of low perfusion rates in the bottom chamber (1-10 µl/min) we could 
prove that cellular oxygen consumption can be used as a surrogate for metabolic 
activity of the hepatocytes. Therefore, the integrated sensor spots represent a 
valuable addition to allow the establishment of models of liver zonation in vitro.  
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4.1.2 Vascular perfusion as a critical parameter for endo-
thelial and hepatocyte cell function 
In vitro, the application of vascular perfusion enables the removal of cellular debris 
and metabolic products thereby avoiding their harmful accumulation. Furthermore, 
shear stress led to morphological adaption and cytoskeletal remodeling of HUVEC 
cell layers (Raasch et al. 2016). In contrast, estimation of physiological shear rates 
affecting hepatocytes in vivo is almost impossible and needs to be evaluated 
carefully for in vitro applications. Whereas very low shear stress (4.7×10-5 dyn/cm²) 
enhanced CYP activity in 2D-hepatocyte cultures (Rashidi et al. 2016), an increase 
(>1.4 dyn/cm²) resulted in continuous alteration of albumin synthesis and finally 
cellular detachment at 20 dyn/cm² (Tanaka et al. 2006). In this thesis it was proven 
that perfusion of HUVEC/macrophage layers, acting as a supportive cellular barrier, 
with 50 µl/min (0.5 dyn/cm²) is sufficient to maintain the function of the static 
HepaRG/LX-2 chamber for up to 96 h. Prodanov et al. (2016), who used a 
comparable liver-on-a-chip with 1 µl/min of vascular perfusion and two distinct cell 
layers, reported an increased albumin and urea secretion compared to static 
conditions during a four week culture period. They claimed that the improved hepatic 
function originates from a better nutrient supply and clearance of metabolites 
(Prodanov et al. 2016). We observed similar effects in our liver-on-a-chip model 
regarding albumin- and urea synthesis. However, our results indicate an enhanced 
CYP3A4 activity under perfused conditions compared to static culture after 96 h. This 
is contrary to the measurements of Prodanov and colleagues who used primary 
human hepatocytes and could be explained by the varying CYP3A4 expression of 
HepaRG cells dependent on their differentiation status (Kanebratt and Andersson 
2008). Additionally, Prodanov et al. (2016) measured the enzyme activity of CYP3A4 
after seven days compared to four days in our model. Therefore, it is necessary to 
verify CYP3A4 function after prolonged culture and investigate additional phase I as 
well as phase II enzymes in our liver-on-a-chip. This is further supported by the 
results of Du et al. (2017) who used primary murine cells in a biochip-based liver 
model and applied a vascular perfusion of 0.1 dyn/cm². The authors observed no 
shear stress-dependent changes of urea synthesis, but an increased CYP1A2 and 
CYP2D6 activity after 24 h of culture (Du et al. 2017). The discussed liver-on-a-chip 
models as well as our model apply a vascularization strategy. Hence, specific media 
for endothelial and epithelial cells can be used according to their requirements.  
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4.1.3 Cellular diversity - the key to hepatic micro-
physiology 
Despite the technical and exogenous control of the microenvironment, cellular com-
position is a critical element to emulate hepatic tissue and related function. To date, 
there is no reported human liver-on-a-chip that contains primary LSECs, KCs, 
hepatocytes and HSCs in a single device. This might be related to their demanding 
culture protocols. The use of cell lines has several advantages, like almost unlimited 
cell availability, better reproducibility, cost-effectiveness and a stable cellular 
phenotype. Furthermore, limited availability of primary cells is associated with their 
isolation from patients who suffer from diseases and get particular medication, which 
increases experimental variance. Therefore, we used in the described liver-on-a-chip 
model the established LX-2 and HepaRG cell lines as surrogates for HSCs and 
primary hepatocytes, respectively. Furthermore, freshly isolated HUVECs mimic the 
endothelial lining of the liver sinusoid that is interspersed with surrogates of KCs 
emulated by monocyte-derived macrophages. In vitro, LSECs rapidly dedifferentiate 
accompanied by the loss of fenestration as well as increasing expression of CD31 on 
the cell surface (Ford et al. 2015), which is contrary to their mature phenotype 
(Poisson et al. 2017). HUVECs up-regulate CD31 during perfusion (Raasch et al. 
2016) and show differences regarding transendothelial migration of monocytes 
compared to LSECs (Zimmermann et al. 2015). Although the HUVECs formed a 
functional vascular barrier in our liver-on-a-chip, it needs to be assessed if LSEC are 
a possible surrogate in future studies. Therefore, investigation of specific 
differentiation markers (e.g. CD31) and functional characteristics (e.g. fenestration, 
scavenger function) is necessary to identify differences regarding the ability of 
HUVECs and LSECs to mimic the physiology of the hepatic vasculature in our model. 
The maintenance of hepatocyte polarization is a critical indicator for their metabolic 
activity. Guillouzo et al. (1993) postulated that hepatic function in vitro is influenced 
by three major regulators: 1) paracrine signaling, 2) cell-cell contacts and 3) 
interaction with ECM. Although we did not implement any exogenous ECM, 
microfluidic models developed by other researchers used a collagen matrix for long 
term stabilization of primary hepatocytes (McCarty et al. 2015, Prodanov et al. 2016). 
Nonetheless, albumin synthesis, urea secretion and bile canaliculi formation was 
shown to be stabilized in co-culture with ECs, which can produce ECM (Kim et al. 
2012). Spheroids containing hepatocytes and stellate cells were further able to form a 
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fibronectin capsule, which was not observed in mono-culture approaches without 
HSCs (Thomas et al. 2005). These results favor the assumption that the HUVECs or 
LX-2 cells in our model contribute to endogenous production of ECM and functional 
stabilization of the cellular microenvironment. Nonetheless, the presence of ECM 
needs to be verified by immunofluorescence staining of the respective proteins. 
Additionally, implementation of exogenous ECM is necessary to determine the impact 
on possible long term maintenance of the liver-on-a-chip beyond four days. 
Another important characteristic of the liver model is the complex microenvironment, 
which is maintained by interactions and close contacts of all cell types. Krause et al. 
(2009) determined that incubation of hepatocytes with HSC-conditioned media and 
their co-culture in direct contact with primary murine HSCs led to a higher 
phosphoenolpyruvate carboxykinase 1 activity. Although, we could not confirm the 
observations of Krause and colleagues regarding CYP3A4 expression of HepaRG 
co-cultured with LX-2, the fully assembled liver-on-a-chip increased the albumin and 
urea synthesis as well as the CYP3A4 expression significantly. Furthermore, 
hepatocyte growth factor (HGF) is secreted by LX-2 cells (Yu et al. 2013) as well as 
HUVECs (Toyoda et al. 2012) and is discussed as a critical mitogen for hepatocytes 
(Michalopoulos 2007). Du and colleagues reported an enhanced production of HGF 
by NPCs in co-culture with primary murine hepatocytes with a cellular arrangement 
comparable to our model (Du et al. 2017). This was associated with a higher CYP-
activity and albumin secretion, which fits to the observations in our human liver-on-a-
chip. Although we did not systematically investigate the influence of direct cell 
contacts and added no exogenous HGF to the media, our results indicate that an 
increased complexity (number of different cell types) is directly affiliated with 
enhanced hepatic function.  
Taken together, our hepatic model enables co-culture of the four main cell types of 
the liver, thereby creating an organotypic, self-maintained physiological micro-
environment. Therefore, this liver-on-a-chip could be a suitable in vitro tool to emulate 
the complex hepatic microphysiology in a reproducible manner. Although we 
detected elongated bile canaliculi between the hepatocytes, which were also 
observed in murine (Li et al. 2010) and human tissues (Nies et al. 2001), substitution 
of the HepaRG cells with primary human hepatocytes is necessary to identify cell 
type-specific drawbacks of our approach and assess the stabilizing effect of the 
complex microenvironment regarding the metabolic capabilities of our liver-on-a-chip. 
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4.2 Inflammation-on-a-chip – a suitable tool for 
translational medicine? 
Inflammation-associated hepatic dysfunction is characterized by interplay of various 
factors, namely immune cell recruitment, cytokine signaling and interaction of 
hepatocytes with NPCs (Adams et al. 2010). The explanatory power of conventional 
in vitro liver models used for studying inflammation is restricted by the lack of certain 
hepatic cell types, by the use of exogenous application of cytokines or a combination 
of both (Klein et al. 2015, Zhou et al. 2015, Rose et al. 2016). Although, those 
applications might be useful for addressing cell type-specific effects, they hardly 
reflect the complex microphysiology and cellular interaction during hepatic 
inflammation. Our established human liver-on-a-chip model was successfully 
characterized by its response to TLR-mediated inflammatory dysfunction. In addition 
to the four cell types previously integrated, we were able to introduce circulating 
monocytes, which were protective against liver damage. Thus, our results indicate 
that the improved microphysiology of the human liver-on-a-chip is associated with a 
specific response to PAMPs, mimicking some aspects of hepatic inflammation. 
4.2.1 TLR-mediated liver dysfunction in a micro-
physiological liver-on-a-chip  
To prove the applicability of our liver-on-a-chip model for studying inflammation we 
investigated the immune reaction after simulation of the receptors TLR-1/2, 4 and 9, 
respectively. All TLR-agonists analyzed require MyD88-dependent signaling and lead 
to activation of NF-κB (Mencin et al. 2009). In contrast, we observed a specific 
cytokine profile dependent on the individual activated TLR receptor. Human 
hepatocytes for example do not contribute to cytokine production after TLR-9 
stimulation (Bröring et al. 2012), which indicates a specific contribution of different 
cells types to TLR-mediated signaling. Nevertheless, we did not examine the 
individual contribution of the different cell types to the total amount of secreted 
cytokines. Importantly, in contrast to other models our liver-on-a-chip does not rely on 
exogenous addition of cytokines, which creates a beneficial, self-contained release 
and interaction of the inflammatory mediators.  
4.2.1.1 Hepatocytes as inflammatory targets 
Stimulations of our liver model with LPS, PAM3CSK4 and ODN-2006 resulted in 
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cholestasis-like hepatocellular dysfunction (reduced MRP-2 expression and CDF 
release) and diminished ApoB expression. Similar results were determined in 
patients suffering from systemic inflammatory response syndrome who showed 
decreased concentrations of ApoB in lymph and blood plasma (Levels et al. 2003). 
Furthermore, there is evidence that patients with cholestasis in sepsis have 
increased bilirubin levels in the serum, which is related to a disturbance in canalicular 
bile excretion via MRP-2 (Nesseler et al. 2012, Bhogal and Sanyal 2013). Another 
important characteristic of our inflammation-on-a-chip model was the elevation of 
glutamate dehydrogenase (GLDH), alanine aminotransferase (ALAT) and aspartate 
aminotransferase (ASAT) after 72 h LPS treatment. An increased serum 
concentration of ALAT is another clinical indicator associated with liver failure during 
sepsis (Bakker et al. 2004). Elevated ASAT and ALAT levels in the PCI mouse model 
of our collaborators also confirmed this.    
In contrast to our expectations, CYP3A4 protein expression and activity was not 
affected by LPS stimulation (100 ng/ml) in our inflammation-on-a-chip model. This is 
contrary to results from human hepatocytes stimulated with a 100-fold higher 
concentration of LPS (10 µg/ml) (Aitken and Morgan 2007). Although they 
determined a fold change of CYP3A4 mRNA below 0.05 compared to control after 
24 h, expression on the protein level was only reduced to approximately 50 % (40 h 
stimulation) and slightly recovered over time. This might be related to a cellular 
desensitization after continuous LPS exposure, which was observed in LSECs and 
hepatocytes by a down-regulation of TLR-signaling (Uhrig et al. 2005, Scott et al. 
2009). The stabilizing effect of the microphysiological environment in association with 
a LPS tolerance might contribute to an improved hepatic metabolism in our 
inflammation-on-a-chip model. This assumption is supported by the minor recovery of 
CYP3A11 (homolog of human CYP3A4) observed after 72 h on the mRNA- and the 
metabolic level in the PCI mouse model of our collaborators.  
4.2.1.2 Sinusoidal activation and recruitment of immune cells  
Despite the presence of immunomodulatory KCs in the liver sinusoids, active 
recruitment of immune cells to the inflamed endothelium is an important regulator of 
the hepatic homeostasis (Shi and Pamer 2011). Static in vitro models lack the option 
of perfusion, which makes it impossible to study mechanisms of circulating 
leucocytes in a physiological manner. We could prove that perfused monocytes are 
actively recruited to the vascular endothelium in our model. Additionally, LPS 
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treatment led to an increased amount of adherent monocytes as well as 
transmigration into the hepatic cell layer. Interestingly, this process was associated 
with a recovery of TLR-mediated dysfunction after 72 h. Du et al. (2017) investigated 
that neutrophil recruitment after LPS treatment is directly correlated to the complexity 
of their liver-on-a-chip model. The presence of ECs, KCs, hepatocytes and HSCs 
resulted in an increased amount of adherent neutrophils. However, they did not 
investigate the effect of the invading immune cells in regard to the function of their 
model (Du et al. 2017).  
Leucocytes are attracted to the activated vascular endothelium by the interaction of 
different adhesion molecules and their respective ligand, i.e. ICAM-1 and VCAM-1 
with integrin αL/β2 und integrin α4/β1 (Blankenberg et al. 2003). It was shown that 
the expression of ICAM-1 is rapidly increased after LPS stimulation in macrophages 
and ECs (Leeuwenberg et al. 1992, Bernatchez et al. 1997). We determined that 
both adhesion molecules were up-regulated after 24 h of LPS incubation, thereby 
causing the activation of the vascular endothelium. Increased expression of those 
surface proteins was also observed in mono-cultures of primary human LSECs after 
treatment with TNF and IFN-γ (Bruns et al. 2015). Although we used HUVECs in our 
model the results indicate the mechanistic capability of these cells regarding 
monocyte recruitment. Additionally, integration of circulating monocytes cells 
increased the shedding of ICAM-1 and VCAM-1, which are discussed as potential 
clinical biomarkers for sepsis patients (Kjaergaard et al. 2016).  
Interestingly, Beattie and colleagues determined a functional cellular adaptation of 
liver-resident macrophages to their microenvironment (Beattie et al. 2016). In their 
study a loss of yolk sac-derived macrophages in mice led to replacement of the KCs 
by monocytes originating from the bone marrow. Although, the populations were 
distinguishable by differentially expressed genes, the response to LPS and their 
phagocytic activity were comparable. This might be important considering the use of 
HUVECs and monocyte-derived macrophages as surrogates for LSECs and KCs in 
our inflammation-on-a-chip. The enhanced hepatic microphysiology of our model 
might contribute to a functional adaptation of these cells, which could be critical for 
the evaluation of obtained results regarding pathophysiological mechanisms during 
liver inflammation. 
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4.2.2 Monocyte-macrophage interaction during hepatic 
inflammation 
After evaluation of the monocyte recruitment mechanisms in our liver-on-a-chip we 
investigated their influence on the tissue-resident macrophages. It was reported that 
circulating monocytes compete for free niches from perished macrophages during 
inflammation (Guilliams and Scott 2017) and contribute to the course of hepatic 
inflammation in dependence of the recruited subtype (Brempelis and Crispe 2016). 
LPS stimulation triggered formation of filopodia and morphological elongation of the 
adherent immune cells in our liver-on-a-chip, indicating an activated phenotype (M1 
polarization). We confirmed the presence of a M1-polarization state by determination 
of an increased expression of the chemokine receptor CD197 (CCR7) as well as an 
increased secretion of IL-6 and TNF compared to the control, which is in line with 
other studies (Mantovani et al. 2002, Martinez and Gordon 2014). Upon monocyte 
recruitment to the site of inflammation, we observed a shift towards an anti-
inflammatory macrophage phenotype (M2) known to mediate tissue regeneration in 
the liver (Tacke and Zimmermann 2014). This was verified by a recovery of albumin 
and urea synthesis as well as maintenance of the vascular barrier integrity. Van den 
Bossche et al. (2016) have provided evidence that activated human M1-polarized 
macrophages are not able to repolarize back to M2. Although we did not examine this 
process, the higher number of recruited monocytes after LPS-treatment fosters the 
assumption that M1 macrophages might be replaced rather than transitioned back to 
M2. Due to the continuous transition of described macrophage markers (Mantovani et 
al. 2002, Martinez and Gordon 2014) it would be difficult to identify a time-dependent 
polarization shift in our liver-on-a-chip by immunofluorescence staining. However, an 
evaluation of the total amount of macrophages before and after LPS treatment, 
combined with a tracking of stained, perfused monocytes could give more support to 
prove the replacement assumption.  
During human sepsis hepatic injury and recovery is balanced by a cascade of pro- 
and anti-inflammatory cytokines (Yan et al. 2014). We observed that circulating 
monocytes contributed significantly to an initial burst of the investigated cytokines 
24 h after their perfusion (LPS conditions). Prolonged LPS exposure led to a 
decrease of IL-6, TNF and IL-1β concentration, which might be related to the 
excessive release of IL-10, a known suppressor of LPS-induced synthesis of the 
mentioned cytokines in human peripheral blood mononuclear cells (Wang et al. 
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1994). Further, IL-10 mediates a decreased NLRP3 inflammasome activation in 
macrophages (Ip et al. 2017) subsequently preventing maturation of IL-1β (Lopez-
Castejon and Brough 2011). Shalova and colleagues demonstrated that isolated 
monocytes from septic patients displayed a pro-inflammatory gene expression profile 
but were tolerant towards LPS stimulation. Nonetheless, they were able to induce 
angiogenesis of HUVECs, which supports the observed recovery of VEC in our liver-
on-a-chip model. Additionally, they suggested that hypoxia-inducible factor-1α (HiF-
1α) is involved in the switch of monocytes to an immunosuppressive phenotype 
(Shalova et al. 2015). Those immunologically repressed monocytes might also 
contribute to the resolution by clearance of LPS, thereby preventing the induction of 
M1-macrophage polarization through specific TLR-signaling (Martinez and Gordon 
2014). Additionally, this was confirmed by the results of Ramachandran et al. (2012) 
who showed that phagocytic activity is associated with transition to a restorative 
phenotype of monocyte-derived macrophages in mice due to enhanced ERK-
signaling. An evaluation of the phagocytic activity of the macrophages in our liver-on-
a-chip in addition to the analysis of CD197, CD163 and the release pro- and anti-
inflammatory cytokines would verify the assumed polarization states and give more 
information about the involved mechanisms of hepatic regeneration. 
We did not investigate all assumed mechanisms in detail, but our observations 
regarding cytokine release, macrophage transition and hepatic tissue repair are in 
agreement with the results from other studies discussed. In this context, HiF-1α and 
the enhanced LPS-clearance by a restorative macrophage phenotype transition 
might be possible mediators for inflammatory resolution and need to be investigated 
in follow-up experiments. 
 
4.3 Novel hypothermal preservation strategy for 
liver-on-a-chip models  
For the first time we showed the applicability of cold storage to preserve our liver-on-
a-chip model for up to two days. Cellular integrity, arrangement and function of the 
microphysiological hepatic in vitro model were almost similar to fresh assembled 
devices after a short recovery time. Based on the TiProtec
®
 and Custodiol-N 
preservation solutions we tested five different formulations and evaluated critical 
components regarding their effects on cell viability, morphology and function after 
hypothermal preservation.  
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4.3.1 Basic components of cold storage solutions  
All storage solutions in this study share some key characteristics to improve the 
outcome of liver-on-a-chip preservation based on previous reports. The pH was 
adjusted to 7.0 in all of the applied storage solutions. In contrast to the physiological 
pH of 7.4, it was reported that mild acidosis is protective to preserve vitality and mito-
chondrial membrane potential of ECs (Wille et al. 2008). The cytotoxic histidine was 
replaced by N-acetylhistidine due to its lower toxicity and similar buffering capacity 
(Rauen et al. 2007b). To further support the energetic metabolism of the cells a 
mixture of different substances was added to prevent metabolic alterations. Whereas 
phosphate is necessary for the synthesis of ATP, addition of glucose stabilized the 
glycolytic activity of ECs (Mertens et al. 1990). Aspartate and α-ketoglutarate were 
supplemented to support the cellular energy management associated with the citrate 
cycle (Wu et al. 2009). Based on previous reports from a modified HTK solution, 
which already comprised tryptophan, the amino acids alanine and glycine were 
added. In combination with sucrose these two substrates were able to prevent 
hepatocyte cell death after cold storage (Pless-Petig et al. 2012). Mechanistically, 
alanine and glycine contribute to a reduction of plasma membrane permeability 
during hypoxia (Frank et al. 2000, Petrat et al. 2012). Carini and colleagues further 
revealed that glycine prevents excessive accumulation of sodium in hepatocytes after 
hypothermic storage (Carini et al. 2000). In summary, a variety of beneficial effects 
were reported for all discussed ingredients during recovery of cold-preserved cells. 
Therefore, we included these additives as the basis for all our storage solutions  
4.3.2 Iron chelators and chloride – critical elements for 
cold storage of liver cells 
To specify the impact of additional storage solution components we tested five 
different derivates of our basic solution with minimal adjustments. In a first approach 
we assessed the outcome after hypothermal preservation regarding morphology, 
viability and protein content of the individual cell layers (vascular and hepatic) for two 
and six days. Overall, HUVECs and macrophages were more sensitive to cold 
storage resulting in a decreased viability and protein content at both investigated time 
points. In contrast, only minor impairments of the HepaRG/LX-2 cell layers were 
observed in lowCl- and low_Defer solutions after six days.  
The lowCl- storage solution is characterized by a chloride concentration of 8.1 mM 
and the addition of lactobionate. This was tested due to the fact that low chloride 
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concentrations (5 mM) had a beneficial effect on cold-stored murine hepatocytes 
(Rauen et al. 2007a). Their study revealed that substitution with lactobionate in a 
modified Krebs-Henseleit buffer prevented iron-independent impairment of these 
cells. Similar observations were made by Pless-Petig et al. (2012) who observed an 
increased cell death of primary murine hepatocytes in a chloride-rich (103.1 mM) cold 
storage buffer. Surprisingly, the same concentration led to a better hypothermal 
preservation of human hepatocytes after rewarming, which indicates species-
dependent differences (Pless et al. 2012). Although HepaRG and LX-2 are human 
cell lines, high concentrations of chloride favored long term storage (six days) in our 
experiments. Further, the protective effect of high chloride concentrations on the 
viability of porcine aortic segments (Wille et al. 2008) could not be demonstrated in 
cold storage of HUVEC/macrophage cell layers. 
The addition of iron chelators to preservatives is critical for the maintenance of cell 
function and viability of various cell types as well as tissues (Rauen et al. 2007a, 
Wille et al. 2008, Arthur et al. 2013). Therefore, we added a combination of 
0.02 mmol/l LK614 and 0.5 mmol/l deferoxamine to all storage solutions, which was 
reported to improve the recovery after hypothermal preservation of blood vessels 
(Wille et al. 2008) and human hepatocytes (Pless et al. 2012). Nonetheless, high 
concentrations of iron chelators are supposed to be cytotoxic (Chaston and Des 
Richardson 2003). In this regard, it was investigated if lower concentrations of 
deferoxamine (0.08 mmol/l), initially used for the TiProtec
®
 solution, are sufficient to 
preserve the distinct cell layers of our model. In contrast, our results indicate that low 
concentrations of deferoxamine (compared to the standard solution) significantly 
reduce viability and protein content of the hepatic cells after six days of cold storage. 
This observation could simply be the result of concentration-dependent chelation 
efficiency, reported for deferoxamine (Richardson et al. 1994). Due to the limited 
amount of storage solution (~250 µl/Well) an exchange during long-term preservation 
(>2 days) might improve the outcome of the low_Defer derivative. Nevertheless, we 
excluded the lowCl- and low_Defer solutions after the determined cellular impairment 
during six days of storage compared to the other three hypothermal preservatives. 
4.3.3 Dextran and PEG enhance liver-on-a-chip storage  
Although the standard solution displayed almost similar outcome for the preservation 
of the hepatic cells, cold storage of HUVECs and macrophages was enhanced after 
addition of dextran and PEG (higher total protein content after six days storage). 
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Therefore, we excluded the standard solution in our study regarding the maintenance 
of functional cellular markers.  
Storage of the hepatic cell layer for six days in either PEG or Dextran solution 
revealed a significant decrease in CYP3A4 expression and number of functional bile 
canaliculi. Although, viability and protein content were not affected these results 
indicate dedifferentiation of the HepaRG, losing their hepatocyte-like phenotype, 
which is essential for marker stabilization (Cerec et al. 2007). Furthermore, the 
amount of CD68-positive macrophages as well as the smooth muscle actin (LX-2 
marker) expression decreased. Therefore, we excluded the long-term storage (six 
days) in the analysis of hypothermal liver-on-a-chip preservation. In a final set of 
experiments we examined the influence of the macromolecular additives PEG and 
dextran regarding the outcome of cold-stored, fully assembled liver-on-a-chip models 
in respect of functional and morphological markers as well as the inflammatory 
responsiveness after LPS treatment. 
Dextran has a molecular weight of 40,000 and was successfully used for hypothermal 
preservation of different organs i.e. lung (Pizanis et al. 2012), kidney (Gallinat et al. 
2013) and liver (Cheng et al. 2005). PEG, on the other hand, improved cold storage 
of hepatocytes by decreasing lipid peroxidation, thereby contributing to stabilization 
of cellular membrane integrity (Mack et al. 1991, Puts et al. 2015). Furthermore, PEG 
is supposed to prevent osmotic cell swelling and acting as a scavenger for free 
radicals, two important requirements for cold storage of cells in general (Shi and Xue 
2016). The addition of either PEG or dextran to the standard preservation solution 
resulted in a full recovery of all cell type specific cell markers determined by immuno-
fluorescence. Further, metabolism of diclofenac and midazolam, as surrogates for 
CYP3A4 and CYP2C9 activity, as well as the function of bile canaliculi were fully 
restored after two days of hypothermal preservation. This is in line with improved 
endothelial morphology and higher bile flow in rat livers after cold storage with PEG 
or dextran, respectively (Cheng et al. 2005, Abbas et al. 2010). Apart from the LDH 
release, which can be explained by the slight viability decrease of the 
HUVEC/macrophage layer after two days, the hepatic cell death markers ALAT, 
ASAT and GLDH were not increased after storage. Additionally, albumin and urea 
synthesis were maintained and comparable to fresh liver-on-a-chip models, 
independent of the applied solution. 
We identified tissue-resident macrophages as important regulators of inflammation 
and hepatocellular dysfunction in our inflammation-on-a-chip model. Therefore, it was 
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tested whether cold storage itself or additives, such as glycine (Petrat et al. 2012), 
affect the outcome of TLR-mediated immune reaction. Overall, we observed only 
slight differences between fresh and stored liver-on-a-chip models after LPS 
stimulation. The tissue-resident macrophages showed an activated morphology 
(filopodia elongation) accompanied by increased cytokine release and impaired 
hepatocyte function. Nonetheless, storage in solution supplemented with dextran led 
to higher IL-1β and IL-10 secretion. Although the morphology of the macrophages 
was comparable to the PEG derivative, the reduced viability of the 
HUVEC/macrophage layer might lead to an accumulation of DAMPs. As a result, this 
could slightly activate the macrophages in the liver-on-a-chip model, a commonly 
observed event in cold-stored liver grafts (Abu-Amara et al. 2010). 
Taken together, our results indicate that the standard solution supplemented with 
PEG (35 kDa) was the most suitable formulation for liver-on-a-chip preservation for 
up to two days. Although this might be sufficient for fast and local distribution, it 
needs to be evaluated if the storage period can be prolonged, as cold storage of 
hepatocytes and vascular cells was reported for at least seven days (Wille et al. 
2008, Pless et al. 2012). Possible strategies would be the continuous exchange of 
the preservative to prevent accumulation of ROS and decreased efficiency of iron 
chelators over time.  
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5 CONCLUSION 
The developed MOTiF-biochip design allows the integration of the four major liver cell 
types, thereby creating a complex, organotypic microenvironment. Perfusion of the 
vascular layer, which acts as a physiological barrier for the hepatic parenchyma, is 
necessary for the effective supply with nutrients and removal of accumulating 
metabolic waste products. The interaction and communication of all cell types 
improves the polarization of hepatocytes resulting in an enhanced metabolization 
rate better resembling the in vivo situation, compared to conventional cell cultures. 
We cultured hepatic cell lines (HepaRG and LX-2) together with freshly isolated 
primary cells (HUVECs and monocytes/macrophages) in our liver-on-a-chip to grant 
reproducibility and cost-effectiveness. Although our approach is associated with 
functional alterations of the respective cell types, the restricted availability as well as 
donor-specific variances of primary liver cells and tissue decreases their applicability 
for the establishment of microphysiological models. Nonetheless, the partial 
replacement of individual cell types is necessary to verify the functional benefits and 
identify drawbacks of the concept. Induction of TLR-mediated inflammation in the 
liver-on-a-chip model revealed pathophysiological similarities to human sepsis and 
mouse models. Thus, it would be interesting to compare the effect of isolated TLR-
agonists with living bacteria in our model and assess the course of hepatic 
inflammation after a complex infection. Targeting the polarization state of monocyte-
derived macrophages, circulating monocytes are critical regulators of hepatocellular 
recovery in the liver-on-a-chip. In this context, the anti-inflammatory cytokine IL-10 
was identified as a potential key mediator of immune tolerance and tissue 
regeneration. However, further studies are needed to confirm the role of IL-10 and its 
involvement in molecular signaling pathways required for liver regeneration after 
acute inflammation. Additionally, it would be of interest to investigate the perfusion of 
classical (CD14++/CD16-) and non-classical (CD14+/CD16++) monocyte subtypes in 
the liver-on-a-chip, respectively. This could provide information about a specific 
recruitment of subsets and related transition of phenotypes during hepatic 
inflammation. To improve the availability of our liver-on-a-chip model also for external 
cooperating researchers we established a cold storage protocol for two days in a 
modified preservation solution. PEG, iron chelators and a high chloride concentration 
were identified as essential components to maintain the hepatic microstructure and 
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inflammatory responsiveness of the liver-on-a-chip. To enable storage beyond two 
days and eradicate limitations of the presented method detailed follow-up studies are 
necessary. Possible strategies would be repeated exchange of the preservative 
during cold storage and individualized storage solutions for the respective cell layers.  
Due to the separated compartments in our biochip, it would be possible to connect 
different microphysiological organs as self-contained modules through vascular 
circulation. Thus, the organ-specific tissue is separated from the vasculature and 
allows the application of individualized cell culture medium. The opportunity of 
variable, modular interconnection offers new possibilities to study systemic organ 
interaction, i.e. gut-liver axis, in vitro. This would be useful for detailed drug screening 
studies (oral or intravenous application) and can be combined with disease models to 
evaluate their therapeutic effect. 
Taken together, our biochip-based, human liver model allows the investigation of 
inflammatory hepatic dysfunction in a complex microphysiological environment. This 
new technology will help to close the gap between static in vitro and in vivo models to 
improve the outcome in translational research in the future.
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